BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: AIDS

BD Biosciences FACS CANTO 流式细胞仪：艾滋病

• 批准号: 7335103
• 负责人: LAWRENCE S LAMB
• 金额: $ 5.24万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7335103
• 关键词: AIDS; gene therapy; neoplasm /cancer; university

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): This application requests funds to purchase the BD Biosciences FACS Canto flow cytometer for the Laboratory for Cellular and Tissue Engineering (LCTE) at the University of Alabama at Birmingham. The instrument will be used to replace a 12 year old BD Biosciences FACS Sort cytometer that has required frequent servicing that at times has impacted the functioning of the laboratory. This instrumentation will allow the laboratory to continue to serve its users well into the future and to expand functionality to allow six-color flow cytometry. The LCTE is a CLIA, CAP, and FACT-compliant core facility supported by the Comprehensive Cancer Center, the Center for AIDS Research, and the Sickle Cell Center. The LCTE provides a platform for translation of promising cellular therapy (including gene-modified cellular therapy) protocols for UAB investigators. The facility provides support from the earliest level of preclinical development to the preparation of clinical grade materials and submission of INDs. Many cell products that are generated in the LCTE are prepared in a clean room environment. The current flow cytometer is located in an adjacent laboratory with a pass-through to the clean suites allowing immediate on-site analysis and consultation with the team that is preparing the graft. Since the graft engineering work often requires multiple steps with flow cytometric analysis required prior to critical decisions during processing, transport of the specimens to another facility for analysis would unnecessarily prolong the processing and potentially compromise the product. In addition, when the LCTE cytometer is not being used for cellular graft evaluation, it is available for overflow work from the Comprehensive Cancer Center, Center for AIDS Research, and the Brain Tumor SPORE NIH-funded investigators that require a 51 OK approved instrument in a CLIA-approved laboratory for their protocols. The Principal Investigator has recently been funded by the University of Alabama Health Services Foundation to undertake a major expansion of the LCTE to include protocols for somatic cell therapy, myocardial regeneration, gene therapy for sickle cell disease, dendritic cell and regulatory cell therapy for autoimmune disorders, and bone regeneration. These protocols, in addition to existing hematopoietic cell therapy and immunotherapy trials nearing approval, will substantially increase the number of users over the next two years. The laboratory will require an instrument that will serve the laboratory in the development and execution of advanced cell therapy trials.

该子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。列出的机构是用于资助的，不一定是研究者的机构。描述（由申请人提供）：本申请要求资金为伯明翰亚拉巴马大学细胞和组织工程实验室（LCTE）购买BD Biosciences FACS Canto流式细胞仪。该仪器将用于替换使用12年的BD Biosciences FACS Sort细胞计数器，该细胞计数器需要频繁维修，有时会影响实验室的功能。该仪器将使实验室能够在未来继续为用户服务，并扩展功能以实现六色流式细胞术。LCTE是由综合癌症中心，艾滋病研究中心和镰状细胞中心支持的CLIA，CAP和FACT合规核心设施。LCTE为UAB研究人员提供了一个翻译有前景的细胞治疗（包括基因修饰的细胞治疗）方案的平台。该机构提供从最早的临床前开发到临床级材料制备和IND提交的支持。在LCTE中产生的许多细胞产物在洁净室环境中制备。目前的流式细胞仪位于相邻的实验室，可直通洁净室，以便立即进行现场分析，并与准备移植物的团队进行协商。由于移植工程工作通常需要多个步骤，在处理期间的关键决策之前需要进行流式细胞术分析，因此将标本运输到另一个设施进行分析将不必要地延长处理时间并可能损害产品。此外，当LCTE细胞仪不用于细胞移植物评估时，它可用于综合癌症中心、艾滋病研究中心和脑肿瘤孢子NIH资助的研究人员的溢出工作，这些研究人员需要在CLIA批准的实验室中使用51 OK批准的仪器进行其方案。主要研究者最近得到了亚拉巴马大学卫生服务基金会的资助，对LCTE进行了重大扩展，以包括体细胞治疗、心肌再生、镰状细胞病基因治疗、自身免疫性疾病树突状细胞和调节细胞治疗以及骨再生的方案。除了现有的造血细胞治疗和免疫治疗试验即将获得批准外，这些方案将在未来两年内大幅增加用户数量。该实验室将需要一台仪器，用于开发和执行先进的细胞治疗试验。